Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Susana N. Banerjee, MD
Advertisement
Articles by Susana N. Banerjee, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
2
Convergent and Divergent Signaling Pathways in Cancer: A Dual-Axis Model for Adaptive Precision Oncology
3
FDA Approves Revumenib in R/R NPM1-Mutant AML
4
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
5
